[HTML][HTML] Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Background The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens,
pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-
33, an epithelial-derived “alarmin.” Astegolimab, a human IgG 2 mAb, selectively inhibits the
IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients
with elevated blood eosinophils (type 2-high), but limited options are available for patients
with low blood eosinophils (type 2-low). Inhibiting IL-33 signaling may target pathogenic …
pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-
33, an epithelial-derived “alarmin.” Astegolimab, a human IgG 2 mAb, selectively inhibits the
IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients
with elevated blood eosinophils (type 2-high), but limited options are available for patients
with low blood eosinophils (type 2-low). Inhibiting IL-33 signaling may target pathogenic …
